---
title: 'VEXAS syndrome: complete molecular remission after hypomethylating therapy'
date: '2024-01-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38214707/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240112170543&v=2.18.0
source: heidelberg[Affiliation]
description: The VEXAS syndrome, a genetically defined autoimmune disease, associated
  with various hematological neoplasms has been attracting growing attention since
  its initial description in 2020. While various therapeutic strategies have been
  explored in case studies, the optimal treatment strategy is still under investigation
  and allogeneic cell transplantation is considered the only curative treatment. Here,
  we describe 2 patients who achieved complete molecular remission of the underlying
  UBA1 ...
disable_comments: true
---
The VEXAS syndrome, a genetically defined autoimmune disease, associated with various hematological neoplasms has been attracting growing attention since its initial description in 2020. While various therapeutic strategies have been explored in case studies, the optimal treatment strategy is still under investigation and allogeneic cell transplantation is considered the only curative treatment. Here, we describe 2 patients who achieved complete molecular remission of the underlying UBA1 ...